DCF — SUTTER ROSEVILLE MEDICAL CENTER
Enterprise Value: $1.1B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$1.1B
Enterprise Value
$308.9M
PV of Cash Flows
$831.3M
PV of Terminal Value
$1.3B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $1.1B | $138.8M | 13.0% | $64.3M | $58.5M |
| Year 2 | $1.1B | $154.3M | 14.0% | $74.8M | $61.8M |
| Year 3 | $1.2B | $170.6M | 15.0% | $85.8M | $64.4M |
| Year 4 | $1.2B | $181.7M | 15.0% | $92.9M | $63.4M |
| Year 5 | $1.2B | $190.3M | 15.0% | $98.0M | $60.8M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $1.1B. Terminal value accounts for 73% of total EV — typical range (60-80%).
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$1.1B
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.12091092208706469
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5